Trial for AML treatments and preventing graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 60 years old (trial has a main range up to under 61)
- Have newly diagnosed AML of specific types (including therapy-related or after MDS, but not APL or certain genetic subtypes)
- Have not received AML treatment before (except limited exceptions like hydroxyurea or EPO)
- Your performance status should be not too limited (ECOG ≤ 3 at diagnosis; later parts often require ECOG ≤ 2)
- Heart, liver, and kidney tests must meet thresholds (including heart pumping strength: LVEF above a minimum)
- Agree to required contraception rules and sign consent forms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
This trial tests whether adding a drug called venetoclax to a standard transplant preparation regimen (called treosulfan-based reduced intensity conditioning) can improve the success of a stem cell transplant for patients with certain blood cancers like AML, MDS/AML, or high-risk MDS. The goal is to see if this combination makes the transplant safer and more effective.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.